Sunday, November 8, 2026

USD/EUR Is 3% Down In The Last 21 Sessions

ViaNews Editorial Team

November 24, 2023

USD/EUR Is 3% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 3.64% for the last 21 sessions. At 17:10 EST on Friday, 24 November, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 3.259% up from its 52-week low and 5.743% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.09%, a negative 0.10%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.34% (last week), 0.36% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: holds above 1.0900 ahead of the eurozone PMI data. According to FXStreet on Thursday, 23 November, "The EUR/USD pair snaps its two-day losing streak and surges above 1.0900 during the Asian session on Thursday. ", " The first upside barrier for EUR/USD is seen at 1.0965, representing the confluence of the upper boundary of the Bollinger Band and a high of November 21. "
  • Eur/usd forex signal: path to 1.100 is still intact despite the pullback - 22 November 2023. According to DailyForex on Wednesday, 22 November, "The EUR/USD pair peaked at 1.0965 on Tuesday and then pulled back after the Fed minutes. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bullish viewBuy the EUR/USD pair and set a take-profit at 1.100."
  • Eur/usd analysis: bulls' control May reach a peak - 22 November 2023. According to DailyForex on Wednesday, 22 November, "Today, the EUR/USD currency pair is on an important date with numerous economic releases in the United States. ", "Conversely, on the same time frame, if the EUR/USD moves towards the support level of 1.0830, it poses a threat to the current dominance of the bulls."
  • Eur/usd rises above 1.0900 ahead of US data. According to FXStreet on Wednesday, 22 November, "The EUR/USD rebounded and is back above 1.0900, trading flat for the day ahead of key US economic data. ", "The EUR/USD is hovering above the 20-day Simple Moving Average (SMA) on the four-hour chart, which stands at 1.0915, near a horizontal resistance level seen at 1.0920. "
  • Eur/usd price analysis: hovers above 1.0900 on ECB lagarde’s hawkish comments. According to FXStreet on Wednesday, 22 November, "A decisive break below the level could put pressure on the EUR/USD pair to navigate the region around the 23.6% Fibonacci retracement at 1.0841.", "Furthermore, the Moving Average Convergence Divergence (MACD) line is above the centerline, with divergence above the signal line, indicating that the EUR/USD pair could re-attempt to target the barrier at the 1.1000 psychological level, following August's high at 1.1064."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com